Latest news with #bioMérieux
Globe and Mail
2 days ago
- Business
- Globe and Mail
Molecular Infectious Disease Testing: A Strategic Imperative in the Next Era of Diagnostic Innovation
"Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany)" The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. In a world increasingly shaped by precision medicine and real-time response to public health threats, Molecular Infectious Disease Testing has emerged as a critical force driving both clinical excellence and strategic business transformation. As healthcare systems, diagnostic developers, and life sciences firms recalibrate in the wake of global disruptions, this once-specialized segment now anchors a new paradigm of proactive, data-driven, and resilient healthcare. The Molecular Infectious Disease Testing Market is poised for significant expansion—powered by evolving pathogen landscapes, digital diagnostics, and next-gen sample-to-answer platforms. For C-suite leaders, this moment presents a rare convergence of public health necessity, commercial scalability, and long-term strategic advantage. Download PDF Brochure: Reframing Diagnostics: From Passive Detection to Intelligent Surveillance Historically, infectious disease diagnostics operated as reactive tools—used to confirm a clinical suspicion. Today, molecular testing reframes this narrative. It offers early detection, predictive analytics, and pathogen-level precision across clinical, commercial, and community settings. From hospital labs to point-of-care environments, molecular diagnostics enable providers to shift from treatment to prevention, aligning with global healthcare imperatives. Molecular platforms—driven by PCR, isothermal amplification, and CRISPR-based innovations—now deliver results in under an hour with laboratory-grade accuracy. This speed-accuracy fusion is not merely a clinical upgrade; it fundamentally redefines operational models for diagnostic providers, healthcare systems, and public health authorities. For enterprises invested in diagnostics, the value proposition is clear: real-time infectious disease visibility fuels smarter resource allocation, reduces hospital burden, and enhances patient outcomes, all while positioning stakeholders as architects of the next diagnostic frontier. Strategic Growth Catalysts: What's Driving Market Acceleration Several macro and micro factors coalesce to propel the Molecular Infectious Disease Testing Market into its next growth phase: 1. Expanding Disease Burden and Antimicrobial Resistance (AMR) The global burden of infectious diseases remains persistent, with resurging pathogens (e.g., RSV, TB, dengue) and emerging zoonotic threats challenging static diagnostic infrastructure. Molecular tools provide the agility and specificity needed to differentiate bacterial from viral infections, a critical step in curbing unnecessary antibiotic use and mitigating AMR. 2. Decentralization of Diagnostics The COVID-19 era taught healthcare an invaluable lesson: decentralization saves lives. With the rise of near-patient and at-home molecular testing platforms, diagnostics are no longer tethered to centralized labs. Enterprises that adapt their go-to-market strategies to support distributed testing architectures —via partnerships with retail clinics, mobile labs, or remote monitoring—will unlock new access points and patient touchpoints. 3. Integration with Digital Health and AI AI and machine learning now bolster molecular diagnostics by enhancing pathogen detection accuracy, analyzing multi-pathogen panels, and predicting outbreak trajectories. Diagnostic systems integrated with EHRs and cloud platforms empower real-time clinical decisions, operational benchmarking, and population-level insights. This digital-molecular fusion presents fertile ground for healthcare innovation. 4. Policy and Funding Momentum Across North America, Europe, and APAC, health authorities are expanding reimbursement codes, issuing preparedness grants, and incentivizing rapid diagnostics in low-resource and high-risk settings. This public-private alignment creates a robust financial scaffold that enables enterprise-level scaling of molecular platforms. Real-World Applications: Impact Across Ecosystems Molecular infectious disease testing is already reshaping operations in high-stakes environments: - Hospitals and Health Systems Rapid syndromic panels reduce patient length of stay, enhance cohorting strategies, and improve antimicrobial stewardship. Molecular diagnostics empower ID specialists to tailor therapy within hours, leading to better outcomes and lower costs per diagnosis. - Pharmaceutical R&D Clinical trial timelines for anti-infectives depend on early, accurate identification of pathogens. Molecular testing accelerates patient enrollment and pathogen profiling, de-risking development pipelines and expediting time-to-market for novel therapeutics. - Public Health and Biosecurity Central and regional agencies are embedding molecular testing into surveillance systems. These platforms offer real-time outbreak detection and genomic surveillance to preempt community spread, identify variants, and inform containment protocols. - Travel, Defense, and Corporate Health Airports, military bases, and corporate campuses now deploy rapid molecular testing for pre-entry screening and ongoing surveillance. This enables safe continuity of operations in mission-critical sectors. Industry Trends and Long-Term Shifts: Preparing for 2030 The next five years will define the blueprint for molecular diagnostics—shaped by three dominant themes: 1. Platform Convergence The future is not single-pathogen but multiplexed and modular. Next-gen systems will support simultaneous detection of viral, bacterial, and fungal targets on customizable panels—driven by cloud-based upgrades and modular chemistry. 2. Global Accessibility Low- and middle-income countries (LMICs) represent a major growth frontier. Companies investing in affordable, ruggedized, solar-compatible molecular platforms stand to gain first-mover advantage in these underserved yet high-need markets. 3. Consumerization and At-Home Testing With rising health literacy and demand for convenience, molecular diagnostics will continue migrating into consumer channels, supported by e-commerce, telehealth integration, and mobile sample logistics. Strategic partnerships with digital health platforms will be crucial for brand relevance and scale. Business Opportunity Landscape: Where the Growth Lies C-suite leaders, investors, and business strategists eyeing the molecular infectious disease testing space should consider five high-potential opportunity zones: A. Horizontal Expansion into Adjacent Conditions Beyond traditional infectious diseases, molecular platforms are being adapted for oncology (viral-driven cancers), transplant monitoring, and immune dysfunction diagnostics. This expands addressable markets and strengthens platform utility. B. Strategic M&A and Licensing Models Smaller diagnostic innovators with novel amplification chemistries, miniaturized hardware, or AI overlays are ripe for acquisition or joint ventures. Corporates seeking to build comprehensive diagnostic ecosystems must prioritize these integrations. C. Private-Public Lab Collaborations Innovative partnerships between diagnostics firms and health agencies (local, federal, or international) will streamline test deployment in underserved geographies, leveraging pooled resources and shared logistics. D. Outcome-Based Reimbursement Models The shift to value-based care compels diagnostics providers to demonstrate impact on outcomes and cost avoidance. Firms that can link molecular testing to reduced admissions, antibiotic usage, or outbreak costs will command premium reimbursements. E. Supply Chain and Manufacturing Localization Post-pandemic disruptions underscore the value of regionalized manufacturing and agile logistics. Companies investing in decentralized, scalable production will enjoy lower lead times, geopolitical risk insulation, and margin protection. A Call to Action: Redefining the Diagnostic Future The evolution of Molecular Infectious Disease Testing represents more than a technological upgrade—it's a business imperative with the potential to redefine diagnostics, reshape public health response, and reimagine the value chain across healthcare. Senior executives who treat molecular testing as a strategic pillar—not a supplemental tool—will lead the industry's transformation. This moment requires bold investments, long-horizon vision, and operational agility. Whether you are a diagnostic innovator, a health system leader, a policy architect, or a life sciences strategist, the time to act is now. The trajectory is clear: the future of infectious disease testing is molecular, digital, decentralized, and intelligent. Those who move early, scale smartly, and innovate continuously will not only lead markets—they will help safeguard global health. For more information, Inquire Now!
Yahoo
22-05-2025
- Business
- Yahoo
GXO extends longstanding partnership with bioMérieux
PARIS, France, May 22, 2025 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO), the world's largest pure-play contract logistics provider, today announced a long-term contract renewal and extension with bioMérieux, a world leader in the field of In Vitro Diagnostics providing solutions to improve patient health and to ensure consumer safety. 'We are delighted that bioMérieux, our partner for over 20 years, renewed the trust they place in GXO. Following a successful overhaul of the distribution of the Reagents range, the extension of the contract for the Instrumentation range marks the continuation of a fruitful collaboration,' said Vincent Ricci, Managing Director, France, GXO. 'Since 2004, we have deployed our unrivaled logistics experience and expertise to optimize bioMérieux's supply chain, and we look forward to continuing this dynamic together, integrating ever more innovation to improve operational efficiency and the experience of our employees.' In order to accommodate new flows, GXO and bioMérieux have worked together to redesign the warehouses' layout while ensuring continuous activity with the same quality of service throughout the project. The redesigned advanced solution integrates automation to increase productivity and quality, managing 6 temperature ranges of reagents with strict regulatory requirements in two warehouses with a total surface area of 39,000 square meters, and deliveries reaching 160 countries. bioMérieux and GXO's operation also now features a unified Warehouse Management System, high scalability and mutualization of storage, including goods receipt, mass storage, and replenishment. GXO is handling inbound and outbound logistics, including shipments to indirect customers, while bioMérieux is optimizing high-value and high-speed processes such as short-term storage picking, packing, and direct customer shipments. Jacques Martinon, International Distribution Center director in France, bioMérieux, said, 'GXO has proven to be a reliable partner with the ability to meet our high standards and comply with the strict regulatory requirements needed for our products. Close collaboration has been the foundation of our success. By focusing on finding solutions, retaining the best ideas, and fostering a collaborative team environment, we are achieving remarkable results.' GXO provides a range of solutions designed to meet the complex needs of healthcare logistics, including critical fulfilment and inventory management for hospital supplies, medical devices, and equipment, including provision to community healthcare providers and home delivery. Across Europe and the U.S., GXO helps ensure full visibility of inventory and orders while managing hundreds of thousands of sensitive, high-value SKUs with meticulous care. GXO's network supports time-sensitive and emergency deliveries, and focuses on process standardization, data accuracy, and regulatory compliance to improve consistency, enhance patient care and help improve the provision of community based primary healthcare. GXO in FranceGXO has been helping customers in France optimize their logistics for several decades and operates over 65 warehouses throughout the country. Currently ranked the #2 logistics service provider in France by Supply Chain Magazine, GXO manages logistics for customers in a variety of sectors, including ecommerce, retail, FMCG and technology. In France, GXO employs nearly 10,000 team members. About GXO LogisticsGXO Logistics, Inc. (NYSE: GXO) is the world's largest pure-play contract logistics provider and is benefiting from the rapid growth of ecommerce, automation and outsourcing. GXO is committed to providing an inclusive, world-class workplace for more than 150,000 team members across more than 1,000 facilities totaling approximately 200 million square feet. The company partners with the world's leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut, USA. Visit for more information and connect with GXO on LinkedIn, X, Facebook, Instagram and YouTube. Media contactsAnne Lafourcade +33 (0)6 75 22 52 90 Matthew Schmidt +1 203-307-2809 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
22-05-2025
- Business
- Associated Press
GXO extends longstanding partnership with bioMérieux
PARIS, France, May 22, 2025 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO), the world's largest pure-play contract logistics provider, today announced a long-term contract renewal and extension with bioMérieux, a world leader in the field of In Vitro Diagnostics providing solutions to improve patient health and to ensure consumer safety. 'We are delighted that bioMérieux, our partner for over 20 years, renewed the trust they place in GXO. Following a successful overhaul of the distribution of the Reagents range, the extension of the contract for the Instrumentation range marks the continuation of a fruitful collaboration,' said Vincent Ricci, Managing Director, France, GXO. 'Since 2004, we have deployed our unrivaled logistics experience and expertise to optimize bioMérieux's supply chain, and we look forward to continuing this dynamic together, integrating ever more innovation to improve operational efficiency and the experience of our employees.' In order to accommodate new flows, GXO and bioMérieux have worked together to redesign the warehouses' layout while ensuring continuous activity with the same quality of service throughout the project. The redesigned advanced solution integrates automation to increase productivity and quality, managing 6 temperature ranges of reagents with strict regulatory requirements in two warehouses with a total surface area of 39,000 square meters, and deliveries reaching 160 countries. bioMérieux and GXO's operation also now features a unified Warehouse Management System, high scalability and mutualization of storage, including goods receipt, mass storage, and replenishment. GXO is handling inbound and outbound logistics, including shipments to indirect customers, while bioMérieux is optimizing high-value and high-speed processes such as short-term storage picking, packing, and direct customer shipments. Jacques Martinon, International Distribution Center director in France, bioMérieux, said, 'GXO has proven to be a reliable partner with the ability to meet our high standards and comply with the strict regulatory requirements needed for our products. Close collaboration has been the foundation of our success. By focusing on finding solutions, retaining the best ideas, and fostering a collaborative team environment, we are achieving remarkable results.' GXO provides a range of solutions designed to meet the complex needs of healthcare logistics, including critical fulfilment and inventory management for hospital supplies, medical devices, and equipment, including provision to community healthcare providers and home delivery. Across Europe and the U.S., GXO helps ensure full visibility of inventory and orders while managing hundreds of thousands of sensitive, high-value SKUs with meticulous care. GXO's network supports time-sensitive and emergency deliveries, and focuses on process standardization, data accuracy, and regulatory compliance to improve consistency, enhance patient care and help improve the provision of community based primary healthcare. GXO in France GXO has been helping customers in France optimize their logistics for several decades and operates over 65 warehouses throughout the country. Currently ranked the #2 logistics service provider in France by Supply Chain Magazine, GXO manages logistics for customers in a variety of sectors, including ecommerce, retail, FMCG and technology. In France, GXO employs nearly 10,000 team members. About GXO Logistics GXO Logistics, Inc. (NYSE: GXO) is the world's largest pure-play contract logistics provider and is benefiting from the rapid growth of ecommerce, automation and outsourcing. GXO is committed to providing an inclusive, world-class workplace for more than 150,000 team members across more than 1,000 facilities totaling approximately 200 million square feet. The company partners with the world's leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut, USA. Visit for more information and connect with GXO on LinkedIn, X, Facebook, Instagram and YouTube. Media contacts Anne Lafourcade +33 (0)6 75 22 52 90 [email protected] Matthew Schmidt +1 203-307-2809 [email protected]
Yahoo
07-03-2025
- Business
- Yahoo
bioMérieux
Full year sales reaching €3,980 million, representing +10.3% organic growth, exceeding the 2024 sales guidance of +8% to +10% MARCY-L'ÉTOILE, France, March 7, 2025 /PRNewswire-PRWeb/ -- The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on March 6 under the chairmanship of Alexandre Mérieux and approved the audited consolidated financial statements for the year ending December 31, 2024. Full year sales reaching €3,980 million, representing +10.3% organic growth, exceeding the 2024 sales guidance of +8% to +10%. The four growth drivers of the GO•28 strategic plan, delivered performances above mid-term guidance while the BIOFIRE® respiratory panels sales were dynamic throughout the year: BIOFIRE® non respiratory panels (non-RP) sales are up +17% with double digit growth in all regions; Acceleration in SPOTFIRE® deployment: €95 million annual sales, outperforming the 2024 €80 million target, and 3,000 instruments installed at the end of 2024; Microbiology up +8.3% driven by reagents volumes and prices increases; Industrial Applications growing steadily, close to +9%, with reagents double digit sales growth in both the pharma and food segments; BIOFIRE® respiratory panels (RP) sales increased +12%, a strong performance driven by the large use of the existing TORCH installed base in the context of a sustained epidemiology throughout the year. Fourth quarter total sales of €1,1 billion, representing +10.1% organic growth. Contributive operating income before non-recurring items (CEBIT) reached €673 million, up +20% at constant exchange rates and scope, exceeding the +12% / +17% annual guidance. The 2024 CEBIT margin stands at 16.9% of sales, up +30bps versus 2023, despite a -€59m currency effect, and a strong +150bps improvement at constant exchange rate and scope. 2024 performance fully in line with the four dimensions of the GO•28 strategic plan: profitable growth at constant exchange rate and scope, driven by teams' focus on simplification and efficiency. Significant achievements on the CSR roadmap, with acceleration in greenhouse gas (GHG) emissions reduction. 2025 Guidance: Sales to grow by at least 7% at constant exchange rates and scope, in line with GO•28 growth ambitions; Contributive operating income before non-recurring items is expected to grow by at least +10% at constant exchange rates and scope. A negative currency effect in the range of €30 million versus 2024 is expected in 2025. GO•28 ambitions include sales growth by +7% CAGR at constant exchange rate and scope over the period 2024/2028, and the achievement of a 20% CEBIT margin in 2028 at constant exchange rate while acting responsibly, in line with our CSR Roadmap. Pierre Boulud, Chief Executive Officer, says: "Our 2024 performance demonstrates bioMérieux's ability to reach our GO•28 ambition. SPOTFIRE® sales accelerated significantly, BIOFIRE® maintained its market leadership in sales and new installations, and we continued to gain market shares in microbiology and industrial applications. In 2024, bioMérieux has also successfully delivered a strong profitability improvement, demonstrating an excellent roll-out of our simplification and efficiency initiatives. On this strong basis, we expect in 2025 our sales to grow by at least 7% at constant exchange rates and scope, and CEBIT to increase by at least 10% at constant exchange rates and scope." Read the full press release. Media Contact Liza Deckelbaum, bioMérieux, 919-645-0782, lizad@ View original content: SOURCE bioMérieux
Yahoo
03-03-2025
- Business
- Yahoo
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
QIAGEN files lawsuit against bioMérieux with German Unified Patent Court to protect key innovations in its QuantiFERON technology QuantiFERON-TB Gold Plus plays a critical role in fighting the spread of TB worldwide VENLO, The Netherlands, March 03, 2025--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringement, reinforcing its commitment to protecting the scientific advancements behind its proprietary QuantiFERON technology. The complaint, filed in the Local Division of the Court of First Instance of the Unified Patent Court (UPC) in Duesseldorf, Germany, concerns European Patent EP 2 276 883 B2. This patent, which is one of many held by QIAGEN protecting the QuantiFERON technology, covers important innovations in QuantiFERON-TB Gold Plus that is used worldwide for TB detection. "Protecting our intellectual property is essential to ensuring continued innovation in infectious disease diagnostics," said Thierry Bernard, CEO of QIAGEN. "QuantiFERON has transformed latent tuberculosis testing, and we will always take the necessary legal steps to defend our proprietary technologies against infringement." This legal action follows QIAGEN's recent success in defending another QuantiFERON-related patent against an invalidity challenge by SD Biosensor in Germany, further demonstrating the strength of QIAGEN's patent portfolio. As a leader in molecular diagnostics, QIAGEN continues to defend its intellectual property to ensure that investments in innovation remain secure and that customers worldwide have access to trusted, high-quality testing solutions. QuantiFERON-TB Gold Plus (QFT-Plus) is widely recommended by leading health organizations, including the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC), for identifying individuals at risk of developing active TB. Unlike traditional skin tests, QFT-Plus provides more reliable and objective results, supporting global TB control efforts. Latent TB infection occurs when the Mycobacterium tuberculosis bacteria remains dormant in the body without causing symptoms. While not contagious, latent TB can progress to active TB, which is a major public health concern. Effective screening and treatment of latent TB are critical for preventing the spread of tuberculosis worldwide. For more information about QuantiFERON technology and QIAGEN's commitment to TB diagnostics, visit About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results and allocations between customer classes, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the "Risk Factors" contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Source: QIAGEN N.V. Category: Corporate View source version on Contacts Contacts QIAGEN: Investor Relations John Gilardi, +49 2103 29 11711Domenica Martorana, +49 2103 29 11244e-mail: ir@ Public Relations Thomas Theuringer, +49 2103 29 11826Lisa Specht, +49 2103 29 14181e-mail: pr@ Sign in to access your portfolio
